Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIGA Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (54)	2/13/2007 2:58:10 PM
From: caly	Read Replies (1) \| Respond to of 160

SIGA Begins Second Human Safety Trial of Its Lead Smallpox Drug Tuesday February 13, 2:45 pm ET NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the launch of a 21-day, escalating, multiple-dose, Phase 1 safety, tolerability and pharmacokinetics human trial of SIGA-246, its lead smallpox drug. The study will examine the safety and pharmacokinetics of SIGA-246 at three different dosages in healthy volunteers when taken once a day for 21 days. "This is one more milestone in the path to FDA approval," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "This important study we believe will confirm the safety findings of an earlier human study and establish the likely human dose of SIGA-246." The trial is being conducted at the Orlando Clinical Research Center in Orlando, FL, and is overseen by Dr. Thomas Marbury in collaboration with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The study is a double-blind, randomized, placebo-controlled, ascending multiple-dose study. SIGA believes that SIGA-246 is the most advanced smallpox treatment currently in development. SIGA-246 represents a new approach to achieve a novel, orally active, antiviral therapeutic. It has already demonstrated significant antiviral activity in various animal trials, including the complete protection against human smallpox virus in primates as well as complete protection in two primate trials against high doses of monkeypox. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C. About SIGA Technologies, Inc. SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).